Trial reportBrain and behavior2017
Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.
Trial report in Brain and behavior, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01380704 (A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Pharmacodynamic Effects of ABT-436 in Major Depressive Disorder Subjects), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Pharmacodynamic Effects of ABT-436 in Major Depressive Disorder Subjects
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Prediction of a clinically effective dose of THY1773, a novel VBiopharmaceutics & drug disposition · 2021Trial
- Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.Brain and behavior · 2017Trial
- Maladaptive Neuroplasticity Under Stress: Insights into Neuronal and Synaptic Changes in the Prefrontal Cortex.Molecular neurobiology · 2025Review
- Neuropeptidergic systems in psychiatric disorders.Frontiers in endocrinology · 2025Review
- Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention.Psychiatry and clinical neurosciences · 2024Review
- The HPA Axis as Target for Depression.Current neuropharmacology · 2024Article
- The ameliorative effect of midazolam on empathy-like behavior in old rats.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Vasopressin as Possible Treatment Option in Autism Spectrum Disorder.Biomedicines · 2023Review
- Relationship between postpartum depression and plasma vasopressin level at 6-8 weeks postpartum: a cross-sectional study.Scientific reports · 2023Article
- Targeting the Arginine Vasopressin VNeuropsychiatric disease and treatment · 2023Review
- Multiple Aspects of Inappropriate Action of Renin-Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric and Neurodegenerative Diseases.Journal of clinical medicine · 2022Review
- Novel Pharmacological Approaches to the Treatment of Depression.Life (Basel, Switzerland) · 2022Review
- Update on GPCR-based targets for the development of novel antidepressants.Molecular psychiatry · 2022Review
- Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.Frontiers in pharmacology · 2022Review
- Vasopressin V1B Receptor Antagonists as Potential Antidepressants.The international journal of neuropsychopharmacology · 2021Review
- Efficacy of Treatments Targeting Hypothalamic-Pituitary-Adrenal Systems for Major Depressive Disorder: A Meta-Analysis.Frontiers in pharmacology · 2021Review
- Sex differences in the hypothalamic-pituitary-adrenal axis: An obstacle to antidepressant drug development?British journal of pharmacology · 2019Review
- Review
- Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.Advances in pharmacological sciences · 2019Review
- Is AD a Stress-Related Disorder? Focus on the HPA Axis and Its Promising Therapeutic Targets.Frontiers in aging neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArginine vasopressin 1B receptor (V
methodsThe V
resultsThe most prevalent safety finding associated with ABT-436 800 mg QD was increased mild-moderate diarrhea (68% v 5%,
conclusionsThe results support further clinical study of the antidepressant potential of ABT-436.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.